Drug Profile
BI 60732
Alternative Names: BI60732Latest Information Update: 04 Oct 2014
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antithrombotics
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 30 Jun 2010 Discontinued - Phase-I for Thrombosis (In volunteers) in Germany (PO)